SCHEMBL13072063

SCHEMBL13072063

COc1ccc2c(c1)CCCN2CC1=NCCN1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HTR1B P28222 1/20 0.45
HSD17B10 Q99714 1/20 0.44
ADRA2A P08913 2/20 0.43
ADRA1D P25100 2/20 0.43
ADRA1A P35348 2/20 0.43
ADRA1B P35368 2/20 0.43
TUBB4A P04350 4/20 0.43
TUBB P07437 4/20 0.43
TUBA3C P0DPH7 4/20 0.43
TUBA1B P68363 4/20 0.43
TUBA4A P68366 4/20 0.43
TUBB4B P68371 4/20 0.43
TUBB3 Q13509 4/20 0.43
TUBB2A Q13885 4/20 0.43
TUBB8 Q3ZCM7 4/20 0.43
TUBA3E Q6PEY2 4/20 0.43
TUBA1A Q71U36 4/20 0.43
TUBA1C Q9BQE3 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13072292 0.91 HDAC1 (0.48) HDAC1HDAC6HTR1BADRA2AADRA1D
SCHEMBL1736709 0.77 HDAC1 (0.48) HDAC1HDAC6HSD17B10TUBB4ATUBB
SCHEMBL12061308 0.76 HRH3 (0.62) HDAC1HDAC6HSD17B10TUBB4ATUBB
SCHEMBL3527567 0.74 TAAR1 (0.65) HDAC1HDAC6HSD17B10TUBB4ATUBB
SCHEMBL10816704 0.74 HSD17B10 (0.51) HDAC1HDAC6HSD17B10TUBB4ATUBB
SCHEMBL10815104 0.73 KMT2A (0.57) HDAC1HDAC6HSD17B10TUBB4ATUBB
SCHEMBL24110550 0.73 HSD17B10 (0.50) HDAC1HDAC6HSD17B10TUBB4ATUBB
SCHEMBL30403752 0.73 HSD17B10 (0.50) HDAC1HDAC6HSD17B10TUBB4ATUBB
SCHEMBL3526150 0.71 TAAR1 (0.60) HDAC1HDAC6TUBB4ATUBBTUBA3C
SCHEMBL24110325 0.71 HDAC1 (0.52) HDAC1HDAC6HSD17B10TUBB4ATUBB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7834044-B2 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder HOFFMAN-LAROCHE INC. (US) 2010-11-16 US disclosed
US-20080113980-A1 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder HOFFMANN-LA ROCHE, INC. 2008-05-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080113980-A1 1-(1H-imidazol-2-ylmethyl)-2,3-dihydro-1H-indole; good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; psychotic disorders; neurodegenerative disorders; malfunction of body temperature homeostasis; cardiovascular disorders; depression, anxiety disorders, bipolar disorder TAAR1, TAAR5, MCHR1 HDAC1 2190/4885HDAC6 2063/4885HTR1B 25/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.